U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07460206) titled 'Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment' on Feb. 26.
Brief Summary: This study is being performed as a single-arm open-label study in order to provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with advanced ccRCC who have progressed on Pembrolizumab as their prior therapy in the adjuvant RCC setting.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
ccRCC
Intervention:
DRUG: Pembrolizumab 200 mg Q3W
The planned dose of pembrolizumab for this study is 200 mg IV every 3 weeks (Q3W). Pembro...